NCT03607890: Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

NCT03607890
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received prior PD-1/PD-L1 inhibitor therapy
Exclusions: Patients with known history or evidence of brain metastases; Patients who have received prior treatment with anti-LAG3
https://ClinicalTrials.gov/show/NCT03607890

Comments are closed.

Up ↑